NEOS S&P 500 High Income ETF vs Teladoc Health Inc — how do they compare? NEOS S&P 500 High Income ETF trades at $53.97 (market cap $12.50B), while Teladoc Health Inc trades at $5.59 (market cap $1.01B). The key difference: NEOS S&P 500 High Income ETF is far larger — about 12.4× Teladoc Health Inc's market cap, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NEOS S&P 500 High Income ETF for 57 Days and Teladoc Health Inc for 39 Days on average.
| SPYI | TDOC | |
|---|---|---|
Market Cap | $12.50B | $1.01B |
Volume | 3,058,962 | 4,668,477 |
Sector | Income / Options Overlay | Health |
52-Week High | $54.42 | $9.72 |
52-Week Low | $47.98 | $4.47 |
Typical Hold Time | 57 Days | 39 Days |
Enterprise Value | — | $1.27B |
Signals from Pluang's Aura AI — not financial advice
SPYI trades at $54.01, down 0.13% with a bullish technical outlook from moving averages but neutral oscillators. The ETF maintains consistent monthly dividend distributions around $0.53-$0.54, though recent analysis highlights concerns about principal erosion from covered call strategies. Media coverage focuses heavily on retirement income strategies and the trade-offs between high yields and capital preservation.
The outlook remains cautious as SPYI faces scrutiny over whether its high income distributions come at the expense of long-term capital growth. While technical indicators suggest near-term strength, fundamental concerns about the sustainability of covered call returns and sequence risk for retirees present significant headwinds for investors seeking both income and principal protection.
Teladoc Health (TDOC) trades at $5.56, down 3.64% on the day, reflecting persistent bearish technical signals and negative earnings. The stock shows weak profitability with a net income margin of -7.13% and negative ROE, though valuation ratios like P/S of 0.4 and EV/EBITDA of 5.89 appear low. Recent news includes a CFO transition and ongoing investor investigations, adding to uncertainty.
The outlook remains challenging due to consecutive net losses and competitive pressures, but the consensus price target of $8.83 suggests potential upside if operational improvements materialize. Key risks include sustained unprofitability, high debt levels, and weak sentiment, requiring careful monitoring of cost management and revenue stabilization efforts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →